U.S. markets open in 8 hours 27 minutes
  • S&P Futures

    4,407.50
    -6.75 (-0.15%)
     
  • Dow Futures

    34,978.00
    -56.00 (-0.16%)
     
  • Nasdaq Futures

    15,101.25
    -16.50 (-0.11%)
     
  • Russell 2000 Futures

    2,207.40
    -6.00 (-0.27%)
     
  • Crude Oil

    72.15
    +0.24 (+0.33%)
     
  • Gold

    1,797.20
    -2.00 (-0.11%)
     
  • Silver

    25.24
    -0.08 (-0.31%)
     
  • EUR/USD

    1.1805
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2760
    0.0000 (0.00%)
     
  • Vix

    17.58
    +0.38 (+2.21%)
     
  • GBP/USD

    1.3827
    +0.0003 (+0.02%)
     
  • USD/JPY

    110.2190
    -0.1560 (-0.14%)
     
  • BTC-USD

    37,009.99
    -1,292.78 (-3.38%)
     
  • CMC Crypto 200

    874.49
    -41.00 (-4.48%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,996.08
    +162.79 (+0.58%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FGEN, CAN and WISH

·3 min read

NEW YORK, NY / ACCESSWIRE / June 7, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

FibroGen, Inc. (NASDAQ:FGEN)

Investors Affected : October 18, 2017 - April 6, 2021

A class action has commenced on behalf of certain shareholders in FibroGen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=16609&from=1

Canaan Inc. (NASDAQ:CAN)

Investors Affected : February 10, 2021 - April 9, 2021

A class action has commenced on behalf of certain shareholders in Canaan Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company's next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan's 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 (“4Q19”) sales and more than 93% quarter-over-quarter compared to its third quarter FY20 (“3Q20”) sales.

Shareholders may find more information at https://securitiesclasslaw.com/securities/canaan-inc-loss-submission-form-2/?id=16609&from=1

Contextlogic Inc. (NASDAQ:WISH)

This lawsuit is on behalf of investors who purchased WISH pursuant or traceable to the registration statement and prospectus issued in connection with ContextLogic's December 16, 2020 initial public stock offering or between December 16, 2020 and May 12, 2021.

A class action has commenced on behalf of certain shareholders in Contextlogic Inc. In the registration statement and prospectus used to conduct the initial public offering and throughout the class period, defendants made materially false and misleading statements about the strength of ContextLogic's business operations and financial prospects by overstating its then-present monthly active users (“MAUs”) and MAU growth trends.

Shareholders may find more information at https://securitiesclasslaw.com/securities/contextlogic-inc-loss-submission-form/?id=16609&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/650645/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-FGEN-CAN-and-WISH